Stock Price Increases Suggest Flu-Oriented Biotechs May Capitalize On Differentiation
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies like Novavax and Dynavax may enjoy improved financial prospects thanks to the way their differentiated approaches to flu therapy could address future outbreaks.